Niewold Timothy B, Kariuki Silvia N, Morgan Gabrielle A, Shrestha Sheela, Pachman Lauren M
University of Chicago Pritzker School of Medicine, Chicago, Illinois 60637, USA.
Arthritis Rheum. 2009 Jun;60(6):1815-24. doi: 10.1002/art.24555.
Interferon-alpha (IFNalpha) has been implicated in the pathogenesis of juvenile dermatomyositis (DM). The aim of this study was to examine serum IFNalpha activity in a cohort of children with juvenile DM to determine relationships between IFNalpha and indicators of disease activity and severity.
Thirty-nine children with definite/probable juvenile DM were included in the study. Serum samples were obtained at the time of diagnosis from 18 untreated patients with juvenile DM. Second samples from 11 of these patients were obtained at 24 months, while they were receiving treatment, and third samples were obtained from 7 of these patients at 36 months. The remaining 21 children were studied 36 months after their initial diagnosis. Serum IFNalpha activity was measured using a functional reporter cell assay.
Patients with juvenile DM had higher serum IFNalpha activity than both pediatric and adult healthy control subjects. In untreated patients, serum IFNalpha activity was positively correlated with serum muscle enzyme levels (P<0.05 for creatine kinase, aspartate aminotransferase, and aldolase) and inversely correlated with the duration of untreated disease (P=0.017). The tumor necrosis factor alpha -308A allele was associated with higher serum IFNalpha levels only in untreated patients (P=0.030). At 36 months, serum IFNalpha levels were inversely correlated with muscle enzyme levels in those patients still requiring therapy and with the skin Disease Activity Score in those patients who had completed therapy (P=0.002).
Serum IFNalpha activity was associated with higher serum levels of muscle-derived enzymes and a shorter duration of untreated disease in patients with newly diagnosed juvenile DM and was inversely correlated with measures of chronic disease activity at 36 months postdiagnosis. These data suggest that IFNalpha could play a role in disease initiation in juvenile DM.
α干扰素(IFNα)与青少年皮肌炎(DM)的发病机制有关。本研究旨在检测一组青少年DM患儿的血清IFNα活性,以确定IFNα与疾病活动度及严重程度指标之间的关系。
本研究纳入39例确诊/疑似青少年DM患儿。在诊断时从18例未经治疗的青少年DM患儿获取血清样本。其中11例患儿在接受治疗24个月时获取第二份样本,7例患儿在36个月时获取第三份样本。其余21例患儿在初次诊断36个月后进行研究。采用功能性报告细胞分析法检测血清IFNα活性。
青少年DM患儿的血清IFNα活性高于儿童和成人健康对照者。在未经治疗的患儿中,血清IFNα活性与血清肌肉酶水平呈正相关(肌酸激酶、天冬氨酸转氨酶和醛缩酶P<0.05),与未经治疗疾病的持续时间呈负相关(P=0.017)。仅在未经治疗的患儿中,肿瘤坏死因子α -308A等位基因与较高的血清IFNα水平相关(P=0.030)。在36个月时,仍需治疗的患儿血清IFNα水平与肌肉酶水平呈负相关,已完成治疗的患儿血清IFNα水平与皮肤疾病活动评分呈负相关(P=0.002)。
新诊断的青少年DM患儿血清IFNα活性与较高的血清肌肉源性酶水平及较短的未经治疗疾病持续时间相关,且与诊断后36个月时的慢性病活动度指标呈负相关。这些数据表明IFNα可能在青少年DM的疾病起始中起作用。